ProCE Banner Activity

Key Considerations for Managing Patients With CLL/SLL

Clinical Thought

In this brief commentary, expert pharmacists review optimal use of BTK inhibitors and venetoclax plus CD20-targeted antibody therapy in patients with CLL/SLL.

Released: March 08, 2023

Expiration: March 06, 2024

No longer available for credit.

Share

Faculty

Victoria Nachar

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Caitlin R. Rausch

Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
MD Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Genentech, a member of the Roche Group

Disclosure

Victoria Nachar, PharmD, BCOP: consultant/advisor/speaker: ADC Therapeutics, Genmab.

Caitlin Rausch, PharmD, BCOP, has no relevant financial relationships to disclose.